Study identifies phenylacetylglutamine (PAGln), a gut microbiome metabolite, as a novel allosteric modulator of β2-adrenergic receptors, offering insights into its role in cardiovascular disease (CVD) risk.
Study reveals challenges and risks for women using anabolic-androgenic steroids
A new study published in Drug and Alcohol Review has revealed critical insights into the challenges and risks faced by women who use anabolic-androgenic steroids
August 28, 2024